Johnson & Johnson to Acquire Austin Biotech Ollin Biosciences in Deal Worth Up to $3.3 Billion
J&J Signs Up to $3.3 Billion Definitive Agreement for Austin's Ollin Biosciences
AUSTIN, Texas — Healthcare giant Johnson & Johnson announced a definitive agreement to acquire Austin-based clinical-stage biotechnology firm Ollin Biosciences in a transaction valued at up to $3.3 billion, including $2.2 billion paid upfront. Ollin focuses on developing therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.
SunHydrogen Shares Outdoor Solar-to-Hydrogen Pilot Update at UT Austin
In clean-energy technology news, SunHydrogen released a milestone video update highlighting outdoor testing of its full-size solar-to-hydrogen panels at its pilot site at the University of Texas at Austin as the technology advances toward commercial deployment.
UT Austin Study in PLOS Biology Explains How the Brain Filters Speech From Noise
Separately, University of Texas at Austin researchers published new findings in PLOS Biology showing how the human brain effortlessly learns to amplify meaningful sounds such as speech and familiar voices over background noise, offering fresh insight into communication disorders.
📰 Related Stories
- UT Austin's 4,000-GPU Horizon Supercomputer Opens as APD Seeks Park Burglary Suspects and TSAHC Names Next Leader Austin • Nov 17, 2026
- 14-Story Hotel Trinity Opens in Downtown Austin as Council Reviews Muny Land Pact and Cookwell Changes Hands Austin • Nov 17, 2026
- Johnson & Johnson to Acquire Austin's Ollin Biosciences in Up to $3.3B Biotech Deal Austin • Nov 17, 2026
- HISD Halts Sale of 12 Properties as Harris County Probes Infant Shooting and Energy Leaders Gather in Houston Houston • Nov 17, 2026